EULAR Study Group on Registers and Observational Drug Studies

Slides:



Advertisements
Similar presentations
BSRBR-RA UK CRN ID: 7302 August 2013 update. Recruitment Certolizumab Must have diagnosis of RA Must be registered within 6 months of first dose of certolizumab.
Advertisements

BSRBR-RA UK CRN ID: 7302 July 2014 update. Recruitment Certolizumab Must have diagnosis of RA Must be registered within 6 months of first dose of certolizumab.
NATIONWIDE PREVALENCE OF RA AND PENETRATION OF DMARDS IN SWEDEN Neovius M, Simard J & Askling J for the ARTIS Study Group Clinical Epidemiology Unit and.
Pragmatic use of data for research, audit and revalidation Will Dixon Health Informatics Unit 10 th anniversary Royal College of Physicians, 15 th Sept.
BSRBR-RA UK CRN ID: 7302 March 2014 update. Recruitment Certolizumab Must have diagnosis of RA Must be registered within 6 months of first dose of certolizumab.
OMICS Group Contact us at: OMICS Group International through its Open Access Initiative is committed to make genuine and.
Coverage & generalisability of the swedish biologics register ARTIS
Safety & Tolerability of Biologics Dubai, United Arab Emirates January 19th, 2009 Prof. Joachim R. Kalden Director emeritus Department of Internal Medicine.
Therapeutic algorithms for Crohn’s disease: Where are we in 2012?
Rituximab for the Treatment of Rheumatoid Arthritis
SICK LEAVE AND DISABILITY PENSION BEFORE AND AFTER INITIATION OF ANTIRHEUMATIC THERAPIES IN CLINICAL PRACTICE Neovius M, Simard JF, Klareskog L & Askling.
HOW LARGE ARE THE PRODUCTIVITY LOSSES IN CONTEMPORARY PATIENTS WITH RA AND HOW SOON IN RELATION TO DIAGNOSIS DO THEY DEVELOP? Neovius M, Simard JF & Askling.
Consultant Rheumatologist
Clinicaloptions.com/Immunology Managing Rheumatoid Arthritis Post Malignancy: A Case-Based Discussion Maria E. Suarez-Almazor, MD, PhD Barnts Family Distinguished.
Professor, Rheumatology Division, Ankara University Medical Faculty
EULAR nurses study group for REsearch and STrategy (REST)
Risk Factors for Rheumatoid Arthritis
Musculoskeletal Health in Europe
Prediction of Response to Targeted Treatment in Rheumatoid Arthritis
Nat. Rev. Rheumatol. doi: /nrrheum
EULAR Study Group for Risk Factors for Rheumatoid Arthritis
Risk Factors for Rheumatoid Arthritis
EULAR nurses study group for REsearch and STrategy (REST)
Algorithm based on the 2016 European League Against Rheumatism (EULAR) recommendations on rheumatoid arthritis (RA) management. Algorithm based on the.
Figure 1 Rheumatoid arthritis development over time in relation to the level of inflammation Figure 1 | Rheumatoid arthritis development over time in relation.
Slide 1: Target population/question
EULAR Study Group for Collaborative Research
Seguridad de los tratamientos biológicos
Figure 3 Simplified EULAR and GRAPPA
Figure 2 Simplified EULAR and GRAPPA
Case Collection in RA: Highlights of an Interactive Workshop
Rheumatoid Arthritis 2015 Guidelines What's New? What's Different?
Biotherapeutics.
Nat. Rev. Rheumatol. doi: /nrrheum
EULAR Study Group on Registers and Observational Drug Studies (RODS)
Figure 1 Simplified EULAR and GRAPPA
Nat. Rev. Rheumatol. doi: /nrrheum
Infections and Biologic Therapy in Rheumatoid Arthritis
Percentage of patients achieving EULAR response
PPD status of CZP-treated patients with RA in the pooled RA safety database (N=4049) at baseline and TB incidence by INH treatment. †One patient who developed.
Patient disposition through 48 weeks in RA-BEYOND
Cumulative incidence of tuberculosis (TB) in certolizumab pegol (CZP)-treated patients with rheumatoid arthritis (RA) in the pooled RA safety database.
Schematic presentation of enrichment through linkages of clinical Rheumatology register data to other national data sources within each of the five Nordic.
Nat. Rev. Cardiol. doi: /nrcardio
The severity of fatigue over 8 years of disease in early rheumatoid arthritis patients. The severity of fatigue over 8 years of disease in early rheumatoid.
Additional efficacy outcomes for the 12-week study of Japanese patients with rheumatoid arthritis treated with baricitinib or placebo. Additional efficacy.
Different treatment strategies in rheumatoid arthritis in relation to radiographic progression (A) number of swollen joints (B) and fatigue severity over.
EULAR-defined characteristics describing arthralgia at risk for RA
Treatment strategy. Treatment strategy. For every patient, changes of treatment were analysed per change, for up to five subsequent therapeutic changes.
The association between alcohol consumption and the severity of MRI-detected inflammation in hand and foot joints of (A) patients with RA and (B) asymptomatic.
Algorithm based on the ASAS-EULAR recommendations for the management of axial spondyloarthritis. Algorithm based on the ASAS-EULAR recommendations for.
Clinical response in patients with early and established RA at month 24. *p
Clinical expertise of GPs and rheumatologists in differentiating patients with arthralgia. Clinical expertise of GPs and rheumatologists in differentiating.
EULAR nurses study group for REsearch and STrategy (REST)
Percentage of patients achieving 20% improvement in the American College of Rheumatology criteria at week 12 by patient demographic and disease characteristics.
EULAR Study Group on SLE
Satisfaction with control of RA
EULAR Study Group for Collaborative Research
EULAR Study Group for Risk Factors for Rheumatoid Arthritis
European League Against Rheumatism points to consider for the use of big data in rheumatic and musculoskeletal diseases.
All registries/studies are anti-TNF focused, excepting ORA (abatacept), AIR (rituximab), and RABBIT (anti-TNFs and anakinra). AIR = Autoimmunity and Rituximab;
EULAR Synovitis Study Group: ESSG
Cardiovascular disease risk assessment capture rates in the NOCAR project, evaluated across diagnosis groups and participating centre. Cardiovascular disease.
 Frequency distribution of the number of fulfilled classification criteria for RA (ACR 1987) in relation to the proportion of positive anti-CCP antibodies.
Effect sizes (95% CI) of clinical variables per treatment group of studies directly comparing different dosages/routes. Effect sizes (95% CI) of clinical.
Incidence rates of hospitalised infection per 100 person-years, standardised for age and sex, among patients with RA from five RA registries and one RA.
Serial determinations of both anti-chromatin and anti-dsDNA antibodies in a patient who developed lupus nephropathy during the study period, showing that.
EULAR Points to consider for the development, evaluation and implementation of mobile health applications aiding self-management in people living with.
Algorithm based on the 2016 European League Against Rheumatism (EULAR) recommendations on rheumatoid arthritis (RA) management. Algorithm based on the.
Women With Psoriasis Are Struggling More Than Men
Presentation transcript:

EULAR Study Group on Registers and Observational Drug Studies REMIT To create a platform for methodological, logistic, and scientific collaboration across European Rheumatology drug registers in order to maximise the potential use of the data collected within each register, to maximise the quality of the scientific outputs within and across registers, and to maximise the exchange of experiences across registers   RECENT ACTIVITIES Completion and publication of a collaborative study on melanomas in relation to biological anti-rheumatic therapies, a joint effort across 11 European biologics registers (1). Completion of a collaborative study on lymphoma characteristics in relation to different RA therapies (2). Organising the EULAR Task Force on RA data harmonisation ((3) and Figure 1). Preparatory work regarding the establishment of a similar type of EULAR activity in the field of GCA. Organising the EULAR RODS meetings (4) (3) The EULAR Task Force on RA data harmonisation (4) The second EULAR RODS meeting 1) Mercer LK, Askling J, Raaschou P, Dixon WG, Dreyer L, Hetland ML, Strangfeld A, Zink A, Mariette X, Finckh A, Canhao H, Iannone F, Zavada J, Morel J, Gottenberg JE, Hyrich KL, Listing J. Risk of invasive melanoma in patients with rheumatoid arthritis treated with biologics: results from a collaborative project of 11 European biologic registers. Ann Rheum Dis. 2017 Feb;76(2):386-391. 2) Louise Mercer 1#, Anne Regierer2#, Xavier Mariette3, William Dixon1, Eva Baecklund4, Karin Hellgren5, Lene Dreyer6, Merete Lund Hetland7, 8, Lene Mellemkjær9, Kimme Hyrich1, 10, Anja Strangfeld2, Angela Zink2,11, Helena Canhao12, M Victoria Hernández13 , Florence Tubach14, Jacques-Eric Gottenberg15, Jacques Morel16, Jakub Zavada17, Florenzo Iannone18, Johan Askling5, Joachim Listing2 The spectrum of lymphomas across different drug treatment groups in rheumatoid arthritis: a European registries collaborative project, submitted 3) Radner H1; Chatzidionysiou K2, Nikiphorou E3, Gossec L4, Hyrich K5, Zabalan C6, van Eijk-Hustings Y7, Williamson P.R8, Balanescu A9, Burmester G.R10, Carmona L11, Dougados M12, Finckh A13, Haugeberg G14, Hetland M.L15, Oliver S16, Porter D17, Raza K18, Ryan P19, Santos M.J20, van der Helm-van Mil A21, van Riel P22, von Krause G23, Zavada J24, Dixon WG25, Askling J2, manuscript